NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adoram Therapeutics

Adoram Therapeutics

Private
SwitzerlandHealthcare & Life Scienceshttps://adoram.ch/

Last Round

Grant

May 5, 2025

Total Funding Raised

$1.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Adoram Therapeutics is a biotechnology company that develops allosteric modulators for the treatment of solid tumors and immune-based diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Infrastructure

Keywords

allosteric modulationG protein-coupled receptorsGPCRsmall molecule therapydrug discovery platformAI drug discoveryadenosine 2A receptorA2ARsolid tumor immunotherapyNAMnegative allosteric modulatorpositive allosteric modulatorPAMin silico drug designbiotech partnershipcomputational biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adoram Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Adoram Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adoram Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 5, 2025
Pre SeedFeb 25, 2025
SeedOct 24, 2024
AcceleratorFeb 23, 2024
GrantApr 11, 2023

Key People

Founding team and executive leadership

David Pejoski

Cofounder, Co-CEO, COO, Board Member

Founding Team

Hesham Ismail HAMED

Co-CEO, Chief Scientific Officer (CSO), Co-Founder And Board Member

Founding Team

Adoram Therapeutics Investors

Notable investors and investment history

Adoram Therapeutics investors
InvestorRounds
FongitSeed, Pre Seed
InnosuisseGrant
Venture KickAccelerator, Grant
InnosuisseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 82% MoM.

  • May 15, 2025

    $1.27M grant received.

Adoram Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adoram Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adoram Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSwitzerland
Employee Range5
Year Founded2022
Last FundingMay 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.